Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Has reproduction · 68
Differential bone morphology and hypoxia activity in skeletal metastases of ER(+) and ER(-) breast cancer.
PMID 39572705 · PMC11582807 · Communications biology · 2024 · 8 claims · 8 setups
ER− MDA-MB-231 breast cancer forms more osteolytic bone metastases than ER+ MCF-7 breast cancer
-
Full-text index only
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer.
PMID 11207044 · PMC2363776 · British journal of cancer · 2001 · 8 claims · 4 setups
The SAFB locus region on chromosome 19p13.2-3 shows a very high rate of loss of heterozygosity (LOH) in primary breast cancer, indicating presence of a breast tumour-suppressor gene locus
-
Full-text index only
Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.
PMID 19789318 · PMC2756455 · Clinical cancer research : an official journal of the American Association for Cancer Research · 2009 · 8 claims · 8 setups
2q37 harbors a tumor suppressor gene important in Wilms tumor pathogenesis
-
Has reproduction · 57
A ChIP-exo screen of 887 Protein Capture Reagents Program transcription factor antibodies in human cells.
PMID 34426512 · PMC8415381 · Genome research · 2021 · 8 claims · 8 setups
About 5% of tested PCRP antibodies showed high-confidence cognate-target enrichment in at least one assay and are strong candidates for further validation.
-
Full-text index only
Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.
PMID 18990233 · PMC2633285 · Molecular cancer · 2008 · 8 claims · 5 setups
PHF2, FANCC and PTCH1 show high frequency of alterations (deletion/methylation) compared to XPA in both early- and late-onset breast carcinoma groups